ATE311363T1 - Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren - Google Patents

Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren

Info

Publication number
ATE311363T1
ATE311363T1 AT99968151T AT99968151T ATE311363T1 AT E311363 T1 ATE311363 T1 AT E311363T1 AT 99968151 T AT99968151 T AT 99968151T AT 99968151 T AT99968151 T AT 99968151T AT E311363 T1 ATE311363 T1 AT E311363T1
Authority
AT
Austria
Prior art keywords
sulfohydroxamate
mek inhibitors
sulfohydroxamic acid
sulfohydroxamic
acid
Prior art date
Application number
AT99968151T
Other languages
English (en)
Inventor
Haile Tecle
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE311363T1 publication Critical patent/ATE311363T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT99968151T 1999-01-13 1999-12-21 Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren ATE311363T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11565299P 1999-01-13 1999-01-13
US12241799P 1999-03-02 1999-03-02
PCT/US1999/030417 WO2000042002A1 (en) 1999-01-13 1999-12-21 Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors

Publications (1)

Publication Number Publication Date
ATE311363T1 true ATE311363T1 (de) 2005-12-15

Family

ID=26813429

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968151T ATE311363T1 (de) 1999-01-13 1999-12-21 Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren

Country Status (10)

Country Link
US (2) US6455582B1 (de)
EP (1) EP1144372B1 (de)
JP (1) JP2002534497A (de)
AT (1) ATE311363T1 (de)
AU (1) AU2482800A (de)
BR (1) BR9916894A (de)
CA (1) CA2349467A1 (de)
DE (1) DE69928697T2 (de)
ES (1) ES2251851T3 (de)
WO (1) WO2000042002A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455582B1 (en) * 1999-01-13 2002-09-24 Warner-Lambert Company Sulohydroxamic acids and sulohyroxamates and their use as MEK inhibitors
AU5912500A (en) * 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
MXPA02008103A (es) * 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
EP1339702A1 (de) 2000-03-15 2003-09-03 Warner-Lambert Company 5-amid-substituierte diarylamine als mek inhibitoren
WO2002017952A2 (en) 2000-09-01 2002-03-07 Van Andel Institute Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma
AU2002255852B2 (en) * 2001-03-22 2006-11-09 Van Andel Research Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
SI2130537T1 (sl) * 2002-03-13 2013-01-31 Array Biopharma, Inc. N3-alkilirani derivati benzimidazola kot inhibitorji mek
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
BRPI0415710A (pt) 2003-10-21 2006-12-19 Warner Lambert Co formas polimórficas de n-[(r)-2,3-dihidróxi-propóxi]-3,4-diflúor-2-(2-flúor-4-io dofenilamino)-benzamida
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
WO2005051302A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
NZ547327A (en) 2003-11-21 2009-08-28 Array Biopharma Inc AKT protein kinase inhibitors
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
DK1802579T3 (da) 2004-10-20 2014-01-20 Merck Serono Sa Derivater af 3-arylaminopyridin
CA2608201C (en) 2005-05-18 2013-12-31 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
JP5324785B2 (ja) 2005-10-28 2013-10-23 武田薬品工業株式会社 複素環アミド化合物及びその用途
DK2489350T3 (en) * 2006-03-17 2014-03-03 Univ Johns Hopkins Med N-hydroxylsulfonamidderivater as new physiologically useful nitroxyldonorer
JP5116245B2 (ja) * 2006-03-24 2013-01-09 地方独立行政法人 東京都立産業技術研究センター 自動分析装置に用いる検量線作成用化合物
US20090239936A1 (en) 2006-05-15 2009-09-24 Yoshikazu Sugimoto Prophylactic and Therapeutic Agent for Cancer
NZ573979A (en) 2006-07-06 2012-02-24 Array Biopharma Inc Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CA2656566C (en) 2006-07-06 2014-06-17 Array Biopharma Inc. Dihydrofuro pyrimidines as akt protein kinase inhibitors
WO2008006039A1 (en) 2006-07-06 2008-01-10 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
MX2009014013A (es) 2007-07-05 2010-01-28 Array Biopharma Inc Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
BRPI0813999A2 (pt) 2007-07-05 2019-10-01 Array Biopharma Inc ciclopentanos de pirimidil como inibidores de akt proteína cinase
EP2247578B1 (de) 2008-01-09 2013-05-22 Array Biopharma, Inc. Hydroxylierte pyrimidylcyclopentane als akt-proteinkinaseinhibitoren
NZ586720A (en) 2008-01-09 2012-11-30 Array Biopharma Inc Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
NZ591498A (en) 2008-08-04 2012-09-28 Merck Patent Gmbh Novel phenylamino isonicotinamide compounds
JP5746630B2 (ja) 2008-11-10 2015-07-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換スルホンアミドフェノキシベンズアミド
WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
US20120263714A1 (en) 2009-10-21 2012-10-18 Bayer Intellectual Property Gmbh Substituted halophenoxybenzamide derivatives
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
KR20140022053A (ko) 2011-04-01 2014-02-21 제넨테크, 인크. Akt 및 mek 억제제 화합물의 조합물, 및 사용 방법
SG194045A1 (en) 2011-04-01 2013-11-29 Genentech Inc Combinations of akt inhibitor compounds and abiraterone, and methods of use
ES2597052T3 (es) 2011-05-25 2017-01-13 Université Paris Descartes Inhibidores de ERK para su uso en el tratamiento de atrofia muscular espinal
CN103204825B (zh) 2012-01-17 2015-03-04 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻唑化合物及其制备方法和用途
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
EP3043822A1 (de) 2013-09-11 2016-07-20 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Zusammensetzungen zur herstellung von kardiomyozyten
CA2935804A1 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
MA41866A (fr) 2015-03-31 2018-02-06 Massachusetts Gen Hospital Molécules à auto-assemblage pour l'administration ciblée de médicaments
WO2017033113A1 (en) 2015-08-21 2017-03-02 Acerta Pharma B.V. Therapeutic combinations of a mek inhibitor and a btk inhibitor
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
CA3147573A1 (en) * 2019-07-17 2021-01-21 2692372 Ontario, Inc. Benzenesulfonamide derivatives and uses thereof
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4073102A4 (de) 2019-12-12 2024-05-08 Ting Therapeutics LLC Zusammensetzungen und verfahren zur prävention und behandlung von gehörverlust
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230134469A (ko) * 2020-11-20 2023-09-21 2692372 온타리오 인크. Kras 변형을 위한 방법 및 조성물
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
CN1163475C (zh) 1997-07-01 2004-08-25 沃尼尔·朗伯公司 4-溴或4-碘苯基氨基苯氧肟酸衍生物及其作为mek抑制剂的用途
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
NL1007364C2 (nl) 1997-10-27 1999-04-28 M Van Den Brand Beheer En Bele Werkwijze voor het toevoeren van tenminste twee fluïda aan een mengkamer, alsmede een dergelijke inrichting.
US6455582B1 (en) * 1999-01-13 2002-09-24 Warner-Lambert Company Sulohydroxamic acids and sulohyroxamates and their use as MEK inhibitors

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
WO2011106298A1 (en) 2010-02-25 2011-09-01 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
US11078540B2 (en) 2010-03-09 2021-08-03 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy

Also Published As

Publication number Publication date
US6455582B1 (en) 2002-09-24
DE69928697D1 (de) 2006-01-05
JP2002534497A (ja) 2002-10-15
US20030045521A1 (en) 2003-03-06
AU2482800A (en) 2000-08-01
CA2349467A1 (en) 2000-07-20
ES2251851T3 (es) 2006-05-01
EP1144372B1 (de) 2005-11-30
WO2000042002A1 (en) 2000-07-20
US6835749B2 (en) 2004-12-28
DE69928697T2 (de) 2006-06-22
BR9916894A (pt) 2001-11-20
EP1144372A1 (de) 2001-10-17

Similar Documents

Publication Publication Date Title
ATE311363T1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
DE60310576D1 (en) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
DE60311662D1 (en) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
PL372926A1 (en) Piperidine-pyridazones and phthalazones as pde4 inhibitors
PT1070056E (pt) Inibidores de pde iii/iv a base de ftalazinona
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
ATE302193T1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
TR200103216T2 (tr) Pirimidinon bileşimleri
ATE234300T1 (de) Benzonaphthyridine als bronchialtherapeutika
DK1000035T3 (da) Substituerede 6-phenylphenanthridiner
EE200000033A (et) Uudsed tetrasoolderivaadid
PT1086096E (pt) Benzamidas com substituintes etra-hidrofuraniloxi como inibidores da fosfodiesterase 4
DE60316984D1 (de) Benzoylsulfonamide als antitumor-mittel
SI1377574T1 (de)
DE602005027866D1 (de) 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4-inhibitoren
TR199903159T2 (xx) Yeni �-Amino ve �-Azido karbonik asit t�revleri.
DE60328621D1 (de) Cyclooct-(en-)yl-derivate zur verwendung als duftstoffe
DE60311000D1 (de) Indolderivate und deren verwendung als 5-ht liganden
ATE340175T1 (de) Imidazo(4,5-böchinolinderivate und ihre verwendung als inhibitoren der induzierbaren no- synthase
DE60204800D1 (de) Bestimmte glycin-derivate als faktor xa inhibitoren zur verwendung in der behandlung von thrombose
ATE388710T1 (de) Phthalazinderivate als phosphodiesterase-4-hemmer
DE602004018276D1 (de) Nitratester von phenylaminothiophen-essigsäurederivaten
ATE338045T1 (de) Substituierte pyrido(1,2-a)pyrimidine und ihre verwendung als nos-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties